In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Learn what a crypto wallet is and how to create one Manoj is a writer who ...

Google's Nano Banana Pro earned a near-perfect score. ChatGPT image ranked second; others often mangled text and faces. Nine tough prompts reveal which AIs are worth subscribing to. When generative AI ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...